BTIG maintains $15 target on Rezolute stock following trial update

BTIG reaffirmed its Buy rating on Rezolute (RZLT) with a $15 price target, citing the completed enrollment of the sunRIZE trial for ersodetug, which is on track for data disclosure in December 2025. The analyst highlights Rezolute's strong financial position and the FDA's Breakthrough Therapy Designation for ersodetug in congenital hyperinsulinism and tumor-induced hypoglycemia. While launch timelines for ersodetug have been adjusted to mid-2027 and 2028, the firm maintains confidence in the drug's potential, supported by positive Phase 2b RIZE study results.

Analysis

BTIG has reaffirmed its Buy rating and $15.00 price target for Rezolute (NASDAQ:RZLT), reflecting sustained analyst conviction. This positive outlook is significantly supported by the completion of enrollment for the sunRIZE clinical trial, which exceeded its target by enrolling 62 participants, keeping the study on track for crucial data disclosure in December 2025. Financially, Rezolute appears well-positioned, with a current ratio of 8.43, more cash than debt, and an anticipated $90 million in gross proceeds from a recent public offering designated for research, development, and operational expenses. The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (BTD) to Rezolute's lead candidate, ersodetug, for both congenital hyperinsulinism (cHI) and tumor-induced hypoglycemia (tumor HI), underscoring its therapeutic potential and potentially expediting its path to market. While BTIG has adjusted its commercial launch timeline estimates for ersodetug to mid-2027 for cHI and 2028 for tumor HI—a slight delay—the $15 price target remains unchanged due to an updated net present value sum-of-the-parts analysis. Analyst confidence in a successful sunRIZE trial is high, based on prior positive Phase 2b RIZE study results, suggesting ersodetug could become a preferred treatment. Despite this optimism and analyst price targets ranging from $9 to $15 indicating significant upside potential from its $242 million valuation, InvestingPro’s Fair Value analysis suggests the stock is currently slightly overvalued, although this assessment does not factor in potential future revenue from these pipeline products. The appointment of biopharma veteran Erik Harris to the Board further strengthens strategic preparations for potential commercialization.

Key Decisions for Investors

• Investors should closely monitor Rezolute's clinical trial progress, particularly the sunRIZE top-line data expected in December 2025, as this is a primary catalyst for the company's valuation.
• Consider the strong analyst support, including a $15 price target and FDA Breakthrough Therapy Designations for ersodetug, against the revised commercial launch timelines now anticipated for mid-2027 and 2028.
• Evaluate the company's solid financial position, bolstered by a recent capital raise, which supports ongoing development, while acknowledging the inherent risks of biopharmaceutical development and the current valuation context provided by InvestingPro's fair value estimate.